A61K36/79

MULTIPLE CONCENTRATE FORMULATION FOR MEDICAL PRODUCTS
20220054411 · 2022-02-24 ·

Two or more concentrates for preparation of a medical device, medical product, or first aid gel. The concentrates of the present disclosure are configured to be added, to be sold, transported, and stored in concentrated form to ease transportation, decrease the cost of transportation and storage, optimize storage space, minimize product cost, ease use of product, militate against risk of microbial contamination, and increase viscosity. A unique preservative gel has been discovered during the new process of heating monolaurin and sorbic acid in propylene glycol before cooling to form an antimicrobial gel. This is used in one of the concentrates as a preservative.

MULTIPLE CONCENTRATE FORMULATION FOR MEDICAL PRODUCTS
20220054411 · 2022-02-24 ·

Two or more concentrates for preparation of a medical device, medical product, or first aid gel. The concentrates of the present disclosure are configured to be added, to be sold, transported, and stored in concentrated form to ease transportation, decrease the cost of transportation and storage, optimize storage space, minimize product cost, ease use of product, militate against risk of microbial contamination, and increase viscosity. A unique preservative gel has been discovered during the new process of heating monolaurin and sorbic acid in propylene glycol before cooling to form an antimicrobial gel. This is used in one of the concentrates as a preservative.

Oral formulations for counteracting effects of aging

An oral formulation as described herein can comprise pomegranate extract, panax ginseng extract, and c. sinensis, where each is present in an amount effective to counteract and/or prevent effects of aging in a subject when administered to the subject. The effects of aging can include age-related changes in gene expression.

Oral formulations for counteracting effects of aging

An oral formulation as described herein can comprise pomegranate extract, panax ginseng extract, and c. sinensis, where each is present in an amount effective to counteract and/or prevent effects of aging in a subject when administered to the subject. The effects of aging can include age-related changes in gene expression.

Oral formulations for counteracting effects of aging

An oral formulation as described herein can comprise pomegranate extract, panax ginseng extract, and c. sinensis, where each is present in an amount effective to counteract and/or prevent effects of aging in a subject when administered to the subject. The effects of aging can include age-related changes in gene expression.

PHARMACEUTICAL COMPOSITIONS AND USE THEREOF
20220054574 · 2022-02-24 ·

The present application relates to methods of preventing, treating or managing a respiratory disease and/or a viral infection (e.g., an influenza virus infection and COVID-19) using a pharmaceutical composition produced from one or more preparations of plant parts. Provided herein are the pharmaceutical compositions produced from the one or more preparations. Also provided herein are methods of producing the pharmaceutical composition from the one or more preparations.

PHARMACEUTICAL COMPOSITIONS AND USE THEREOF
20220054574 · 2022-02-24 ·

The present application relates to methods of preventing, treating or managing a respiratory disease and/or a viral infection (e.g., an influenza virus infection and COVID-19) using a pharmaceutical composition produced from one or more preparations of plant parts. Provided herein are the pharmaceutical compositions produced from the one or more preparations. Also provided herein are methods of producing the pharmaceutical composition from the one or more preparations.

PHARMACEUTICAL COMPOSITIONS AND USE THEREOF
20220054574 · 2022-02-24 ·

The present application relates to methods of preventing, treating or managing a respiratory disease and/or a viral infection (e.g., an influenza virus infection and COVID-19) using a pharmaceutical composition produced from one or more preparations of plant parts. Provided herein are the pharmaceutical compositions produced from the one or more preparations. Also provided herein are methods of producing the pharmaceutical composition from the one or more preparations.

PEPTIDE AND OSIDE EXTRACT OF SCHIZANDRA FRUIT AND IMPROVEMENT IN THE RESPONSE OF THE CUTANEOUS NEUROSENSORY SYSTEM

The present invention relates to the use of a peptide and glycoside extract of Schizandra fruit as a cutaneous neurosensory agent, for improving the response of the cutaneous neurosensory system, in particular for: —improving cutaneous innervation in the basal state, —combatting age-related loss of cutaneous innervation in the basal state, advantageously for preventing loss of the cutaneous sensitivity and/or combatting thinning of the epidermis, and/or—improving cutaneous perception of the environment, more particularly for combatting burns, extreme cold and/or pain.

PEPTIDE AND OSIDE EXTRACT OF SCHIZANDRA FRUIT AND IMPROVEMENT IN THE RESPONSE OF THE CUTANEOUS NEUROSENSORY SYSTEM

The present invention relates to the use of a peptide and glycoside extract of Schizandra fruit as a cutaneous neurosensory agent, for improving the response of the cutaneous neurosensory system, in particular for: —improving cutaneous innervation in the basal state, —combatting age-related loss of cutaneous innervation in the basal state, advantageously for preventing loss of the cutaneous sensitivity and/or combatting thinning of the epidermis, and/or—improving cutaneous perception of the environment, more particularly for combatting burns, extreme cold and/or pain.